




RealRate

PHARMACEUTICAL 2021

Kiniksa Pharmaceuticals Ltd.
Rank 227 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2021

Kiniksa Pharmaceuticals Ltd. Rank 227 of 409

The relative strengths and weaknesses of Kiniksa Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 200% points. The greatest weakness of Kiniksa Pharmaceuticals Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is -161%, being 193% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	333,249
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,846
Liabilities, Non-Current	5,683
Other Assets	12,164
Other Compr. Net Income	-67
Other Expenses	5,152
Other Liabilities	0
Other Net Income	1,134
Property and Equipment	4,051
Research and Development	112,042
Revenues	0
Selling, General and Administrative Expense	45,321

Output Variable	Value in 1000 USD
Assets	349,464
Liabilities	37,529
Expenses	162,515
Stockholders Equity	311,935
Net Income	-161,381
Comprehensive Net Income	-161,414
Economic Capital Ratio	-161%

